<DOC>
	<DOCNO>NCT02615730</DOCNO>
	<brief_summary>This Phase Ib/IIa , open-label , non-randomized , dose-escalation , multi-center study evaluate safety , tolerability , pharmacokinetics ( PK ) , clinical activity oral GSK2636771 combination intravenous ( IV ) paclitaxel two independent subject population : subject PTEN-deficient , advance gastric adenocarcinoma . This study conduct two phase : Dose Escalation Phase Dose Expansion Phase . The Dose Escalation Phase ( Phase Ib ) design determine maximum tolerate dose ( MTD ) recommend Phase II dose ( RP2D ) GSK2636771 administer combination paclitaxel . The Dose Expansion Phase ( Phase IIa ) evaluate safety clinical activity RP2D determine Dose Escalation Phase .</brief_summary>
	<brief_title>PI3Kβ Selective Inhibitor With Paclitaxel , Advanced Gastric Adenocarcinoma</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Inclusion criterion : 1. histologically cytologically confirm diagnosis advance gastric adenocarcinoma 2 . Has PTENdeficient tumor document archival fresh ( biopsy ) tumor tissue show genomic alteration PI3K pathway gene ( PIK3CB , PI3KR1 , PTEN , etc . ) assess local laboratory . 3 . Has prior taxane exposure ( prefer ) least 6 month since last taxane exposure . 4 . Eastern Cooperative Oncology Group performance status 0 1 5. measurable evaluable disease determine RECIST 1.1 . 6 . Is able swallow retain orally administer medication 7. adequate baseline organ function Exclusion criterion 1. prior treatment AKT , mammalian target rapamycin ( mTOR ) inhibitor PI3K pathway inhibitor 2 . Has unresolved Grade 2 ( per CTCAE v4.0 ) toxicity previous anticancer therapy time enrollment neuropathy , except alopecia Grade 2 anemia ( hemoglobin ≥9.0 g/dL ) 3 . Has CNS metastases 4 . Has QTc interval &gt; 450 msec QTc &gt; 480 msec subject bundle branch block ( BBB ) 5 . Has know immediate delay hypersensitivity reaction idiosyncrasy drug chemically relate GSK2636771 hypersensitivity drug formulate polyoxyl 35 castor oil , NF paclitaxel .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>